Open an account

Acurx Pharmaceuticals

ACXP · NASDAQ

$1.14+$0.00 (+0.00%)TodayMarket closed ·
Prev close $1.14

About ACXP

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Employees
4
Headquarters
Staten Island, New York
Listed
Jun 25, 2021
Sector
Health Care
Industry
Biotechnology
Website
acurxpharma.com

ACXP key statistics

Market cap
6.34M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
102.23K
Volume
68.30K
Open price
$1.16
High today
$1.18
Low today
$1.12
52 Week high
$7.54
52 Week low
$1.07

Acurx Pharmaceuticals (ACXP) at a glance

As of Oct 20, 2026, Acurx Pharmaceuticals (ACXP) shares are priced at $1.14, giving the company a market cap of 6.34M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.12 and $1.18. The current price is 2.2% above the day's low and 3.4% below its high.

Volume so far is 68.30K shares, below the average of 102.23K shares a day.

Over the past year Acurx Pharmaceuticals has ranged from $1.07 to $7.54, and now sits 1% of the way up that range.

Acurx Pharmaceuticals met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.53 per share against an estimate of -$0.3842.

The average analyst price target is $17.34, 1421.1% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $17.34
Low
$10.10
Now
$1.14
High
$32.55

ACXP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 22.5% on average.

  1. Q3 FY24: reported -$3.40 per share against an estimate of -$4.08
  2. Q4 FY24: reported -$3.20 per share against an estimate of -$3.67
  3. Q1 FY25: reported -$2.20 per share against an estimate of -$3.06
  4. Q2 FY25: reported -$1.89 per share against an estimate of -$2.31
  5. Q3 FY25: reported -$1.23 per share against an estimate of -$1.34
  6. Q4 FY25: reported -$0.31 per share against an estimate of -$1.01
  7. Q1 FY26: reported -$0.62 per share against an estimate of -$0.6477
  8. Q2 FY26: reported -$0.53 per share against an estimate of -$0.3842

ACXP news

  • Press releasePRNewswire

    Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

  • Press releasePRNewswire

    Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures

  • Press releasePRNewswire

    Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

  • Press releasePRNewswire

    Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

  • Press releasePRNewswire

    Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

  • Press releasePRNewswire

    Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

  • Press releasePRNewswire

    FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

  • Press releasePRNewswire

    Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection

Similar companies

Companies in the same industry as Acurx Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.